
Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of $7.74 per share for the year. The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million.
Separately, William Blair raised Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.
View Our Latest Stock Report on Zealand Pharma A/S
Zealand Pharma A/S Stock Down 5.5%
Zealand Pharma A/S stock traded down $4.05 during midday trading on Thursday, reaching $70.08. The stock had a trading volume of 1,525 shares, compared to its average volume of 923. Zealand Pharma A/S has a 12 month low of $57.97 and a 12 month high of $141.74. The company has a market capitalization of $4.98 billion, a P/E ratio of -29.69 and a beta of 0.74. The company has a fifty day moving average price of $66.60 and a two-hundred day moving average price of $85.37. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03.
Zealand Pharma A/S Company Profile
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Featured Stories

Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.